Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The expansion includes a larger technical and service team and increased local procurement
The state-of-the-art facility is expected to be commissioned over the next three years
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Subscribe To Our Newsletter & Stay Updated
